Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Can engineering outfit Spirax revive its fortunes?

AJ Bell is an easy to use, award-winning platform Open an account
We've accounts to suit every investing need, and free guides and special offers to help you get the most from them.
You can get a few handy suggestions, or even get our experts to do the hard work for you – by picking one of our simple investment ideas.
All the resources you need to choose your shares, from market data to the latest investment news and analysis.
Funds offer an easier way to build your portfolio – we’ve got everything you need to choose the right one.
Starting to save for a pension, approaching retirement, or after an explainer on pension jargon? We can help.
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
UK engineering business Spirax (SPX) is expected to deliver mid-single digit organic revenue growth for 2024 when it announces results on 11 March.
As a reminder, the company (once known as Spirax-Sarco Engineering) is a FTSE 100 constituent focused on steam, thermal electric and niche pumping solutions, across a wide range of end-markets.
After a period in the doldrums which has seen the shares drop to £72.05 from the £170.45 peak in late 2021, a recently installed management team will be looking to demonstrate they can turn around the company's fortunes. CEO Nimesh Patel took the helm at the beginning of 2024 and was joined by chief financial officer Louisa Burdett in July of last year.
Spirax has undergone a material shift through acquisitions to position itself for long-term drivers such as the energy transition but this, in turn, has arguably increased the complexity and risk around the business.
Berenberg analyst Andrew Simms comments: 'Spirax had a whirlwind 2024. Rising optimism for a 2024 recovery sent the shares up by 10% in Q1 but the extended Biopharma destocking, slower semiconductor market and cyclical weakness resulted in a 40% peak-to-trough fall.
'With markets that deteriorated rather than improved, H1 organic growth in the Steam segment was -1%, while further internal and external headwinds became apparent with declining margins exacerbating a lower-than-expected top line.
'The company’s capital markets day in October 2024 provided some incremental information regarding the scale of the growth opportunity and showcased the new management set-up while highlighting increasing investment requirements. We remain unconvinced that the event achieved what the company envisaged.'
Simms notes an expected fourth-quarter weighting to the company's full-year numbers so the upcoming release could be key in showing if Patel and Burdett are making any tangible progress with their recovery strategy.
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.